727 research outputs found
G. Piccaluga. Minutal. Saggi di storia delle religioni
No full textTurcan Robert. G. Piccaluga. Minutal. Saggi di storia delle religioni. In: Revue de l'histoire des religions, tome 190, n°2, 1976. pp. 191-192
G. Piccaluga, Minutal. Saggi di storia delle religioni, 1974
No full textLévêque Pierre. G. Piccaluga, Minutal. Saggi di storia delle religioni, 1974. In: Revue des Études Anciennes. Tome 80, 1978, n°3-4. pp. 340-341
G. Piccaluga, Minutal. Saggi di storia delle religioni, 1974
No full textLévêque Pierre. G. Piccaluga, Minutal. Saggi di storia delle religioni, 1974. In: Revue des Études Anciennes. Tome 80, 1978, n°3-4. pp. 340-341
G. Piccaluga. Terminus. I segni di confine nella religione romana
No full textTurcan Robert. G. Piccaluga. Terminus. I segni di confine nella religione romana. In: Revue de l'histoire des religions, tome 190, n°2, 1976. pp. 192-194
Commercializing technology from university-industry collaborations: A configurational perspective on organizational factors
No full textHematopoietic stem cell transplantation for adult acute lymphoblastic leukemia
No full textThe most recent clinical trials on adult acute lymphoid leukaemia (ALL) have shown
complete remission and disease-free survival (DFS) rates of 80-85% and 30-40%, respectively
(Annino, et al, Durrant, et al, Kantarjian, et al, Larson, et al, Ribera, et al, Rowe). Intensified
consolidation, particularly with high-dose methotrexate and high-dose cytarabine, may be
one of the reasons for the improved outcome in recent series (Bassan and Hoelzer, Hoelzer
and Gokbuget, Kebriaei and Larson). In addition, risk-adapted and subtype-oriented
therapy may have contributed to this better outcome. However, the long term outcome of
adult patients is still dismal, with approximately one third of the cases only being cured. At
present, therapeutic options include conventional chemotherapy (CHT), high dose therapy
with autologous and, especially, allogeneic stem cells transplantation (SCT) and, for certain
subsets, such as BCR-ABL1+ ALL, specific targeted therapy (Piccaluga, et al).
Although SCT has been used in adult ALL for more than 20 years, its role remains
controversial as demonstrated by conflicting results in various studies. Previous casecontrolled
studies did not show that allogeneic SCT (alloSCT) provided any advantage over
CHT (Horowitz, et al, Zhang, et al) while in some studies there was an advantage, but
restricted to young adults (Oh, et al). The number of controlled published or ongoing trials is
remarkably small and some of them did not include both standard-risk and high-risk
patients. Thus, it is difficult to draw definitive conclusions from their results. In fact, while
some authors did not report any differences between alloSCT and chemotherapy or
autologous SCT (ASCT)(Gupta, et al, Labar, et al), others only found differences favouring
allogeneic SCT in standard risk (Goldstone, et al) or high-risk ALL patients (Sebban, et al,
Thiebaut, et al, Thomas, et al). In this chapter, the Authors reviewed data concerning alloSCT in adult ALL and discuss
current controversial and possible perspectives
Managing proof-of-concept (PoC) programs in public research organizations: a dynamic capabilities perspective
No full textPurpose
This paper aims to explore how the implementation of gap funding instruments such as Proof-of-Concept (PoC) programs can contribute to developing dynamic capabilities in Public Research Organizations (PROs). The research investigates the processes and practices underlying PoC programs that may provide potential foundations for dynamic capabilities (i.e. organizational microfoundations) in PROs operating within a technology transfer setting.
Design/methodology/approach
We conducted an exploratory qualitative study through 37 interviews with the employees of PROs involved in the valorization of 155 technologies within 24 PoC programs. We iteratively triangulated those data with secondary sources.
Findings
We identified four key processes (i.e. management, selection, monitoring and valorization) and their associated practices that act as organizational microfoundations, enhancing the emergence of dynamic capabilities in PROs. We articulated six propositions to advance theoretical understandings about gap funding instruments and dynamic capabilities in technology transfer settings.
Originality/value
This study extends prior research on gap funding instruments by examining the less explored processes and practices underpinning PoC programs, demonstrating their role in enhancing PROs to foster external engagement and adaptation to fast-changing environments. Furthermore, it contributes to dynamic capabilities literature by unpacking those microfoundations that enable PROs to build sensing, seizing and reconfiguring capabilities when interacting with the external environment
- …
